---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-002985"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:39:19.412451+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Relmada reports positive preclinical psilocybin data for MASLD; Phase 1 in early 2024

## Summary
- Low-dose psilocybin (0.05 mg/kg, daily oral) in HFHFD mice reduced liver steatosis, body weight (12% reduction), and fasting blood glucose (p<0.05).
- Mechanism involves 5-HT-2A receptor agonism, distinct from GLP-1 agents; restored plasma/liver triglyceride levels to normal-diet levels.
- Company to initiate single-ascending dose Phase 1 trial in obese MASLD patients in early 2024.
- Data to be presented at AASLD The Liver Meeting 2023 (Nov 10-14, 2023, Boston).

## SEC filing metadata
- accession: 0001013762-23-002985
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000101376223002985/0001013762-23-002985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000101376223002985/ea186600-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-002985
- JSON: https://secwatch.observer/filing/0001013762-23-002985.json
- Plain text: https://secwatch.observer/filing/0001013762-23-002985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.